Login:
 
Savill P. Discontinuing rivaroxaban affects outcomes in atherosclerotic disease. Practitioner July/August 2021;265(1850):5

Discontinuing rivaroxaban affects outcomes in atherosclerotic disease

26 Jul 2021Registered users

The combination of rivaroxaban and aspirin compared with aspirin alone significantly reduced cardiovascular outcomes in patients with chronic coronary artery disease or peripheral artery disease, a large study has shown. However, when rivaroxaban therapy was discontinued at the end of the trial the benefits were lost and a higher stroke rate was seen in those originally randomised to combination therapy.

Registered usersThis article can only be accessed if you are a registered user of thepractitioner.co.uk or a subscriber to The Practitioner.

To buy this article (£25+tax) copy the article citation above and click Buy article